Skip to content
Open access

Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors.

Sep 2026 · Clinical Pharmacokinetics · 0 citations · 14 references
Medicine

TL;DR

Target attainment was suboptimal for most TKIs, supporting the need for TDM-guided optimisation and individualised dosing, and Associations between TKI exposure and renal, hepatic, and haematological parameters further support personalised treatment strategies.

Abstract

Background

AND

Objective

Tyrosine kinase inhibitors (TKIs) are targeted cancer therapies. However, TKIs are still limited due to their high inter-individual variability. This study evaluated target attainment using therapeutic drug monitoring (TDM) data from 12 TKIs, and investigated biochemical and patient-related characteristics influencing TKI pharmacokinetics (PK)

Methods

This single-centre retrospective study included cancer patients treated with TKIs between January 2020 and August 2024. Demographic, clinical, and biochemical data were extracted from electronic health records. Univariate and multivariate linear mixed models were used to identify factors associated with TKI PK.

Results

A total of 1237 TKI concentrations from 309 patients were included. Target attainment percentages were: 74.6% for alectinib; 70% for bosutinib; 49.9-61.9% for imatinib depending on the indication; 88.9% for nilotinib; 50% for pazopanib; 50% for ponatinib; 89.5% for regorafenib; 26.6% for sunitinib; ibrutinib, lenvatinib and trametinib had too few data for formal assessment; 40-87.5% for dasatinib, depending on indication and parameter (Cmax or Cmin). A mixed linear model analysis identified key parameters correlated with TKI concentrations. Glomerular filtration rate was correlated with alectinib, imatinib, and sunitinib. Alkaline phosphatase (ALP), bilirubin, and Gamma-GT correlated with alectinib and ALP with imatinib. Albumin and thrombocytes correlated with imatinib, thrombocytes with pazopanib, absolute neutrophiles count (ANC) with ponatinib, and haematocrit with regorafenib.

Conclusion

Target attainment was suboptimal for most TKIs, supporting the need for TDM-guided optimisation and individualised dosing. Associations between TKI exposure and renal, hepatic, and haematological parameters further support personalised treatment strategies.

Read PDF

Similar papers

Open access Oct 2026

Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data

Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.

Grietje van Elp, Maikel Borg, J. Bos et al. · 0 citations
Open access Aug 2026

Association of baseline serum albumin with treatment-related toxicities in patients receiving tyrosine kinase inhibitors: a real-world cohort study

Tyrosine kinase inhibitors (TKIs) are widely used across multiple malignancies, but treatment-related toxicities remain a major cause of healthcare utilization and treatment modification. Serum albumin is a routinely available biomarker that reflects nutritional status, systemic inflammation, and physiologic vuln...

Ahmed S. Alanazi, Mohammed A. Alnuhait, Norah M. Almutairi et al. · 0 citations
Clinical trial Open access Oct 2026

Population Pharmacokinetics of Cabozantinib: Updated Analyses Including Data in Combination With Atezolizumab in Patients With Castration‐Resistant Prostate Cancer and Other Tumor Types

Cabozantinib is a small‐molecule tyrosine kinase inhibitor approved for the treatment of various locally advanced or metastatic solid tumors. The phase 1b COSMIC‐021 study evaluated cabozantinib as a monotherapy or in combination with atezolizumab in patients with advanced solid tumors, including castration‐resistant p...

Jason H. Williams, Han-Bin Li, A. Othman · 0 citations
#software testing Review Open access Sep 2026

Tyrosine kinase inhibitors for chronic myeloid leukemia: a landscape analysis of global clinical trials based on public registries

Global trials are geographically and developmentally unbalanced, with incomplete public availability of trial results, and future research should strengthen international collaboration, optimize trial phase distribution, support novel agent development, and promote timely and complete public disclosure of trial results...

Li-Chuan Zhang, Qi Tian, Ya-Lin Tang et al. · 0 citations
Sep 2026

Beta-Lactam Dose Optimization Using Therapeutic Drug Monitoring in Pediatric Patients.

OBJECTIVE Beta-lactam therapeutic drug monitoring (BL-TDM) is underused in pediatric patients where drug exposure is highly variable. This study evaluated the pharmacokinetic/pharmacodynamic (PK/PD) target attainment of BLs in pediatrics. PATIENTS AND METHODS A retrospective observational cohort study of BL-TDM was c...

V. Venugopalan, K. Manasco, Ahmad Hachem et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.